AptarGroup, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ATR | STVN | WST | AVTR | SOLV | ICUI | |
|---|---|---|---|---|---|---|
| Market cap | 7.56B | 5.25B | 25.87B | 10.48B | 14.52B | 4.10B |
| P/E (TTM) | 21.5 | 33.8 | 47.1 | — | 10.4 | 137.7 |
| Forward P/E | 19.1 | 23.1 | 36.8 | 17.7 | 11.8 | 17.0 |
| Price/book | 2.9 | 3.0 | 8.7 | 1.9 | 3.0 | 1.9 |
| Dividend yield | 1.59% | 0.32% | 0.24% | — | — | — |
| 1-year change | −8.36% | −16.77% | +39.44% | +11.36% | +23.15% | +37.90% |
| Today | −1.19% | −0.82% | +0.44% | −1.15% | −2.27% | +2.24% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.
Latest news
All ATR news ›ATR Initiates Coverage On AptarGroup -- Neutral Rating by UBS
On October 3, 2023, AptarGroup ATR received a Neutral rating from UBS, with analyst Anojja Shah leading the coverage. This is a new initiation with a current price target set at $135.00. The Neutral rating from UBS marks a significant…
Bespak Secures Exclusive Access to SNBL Nasal Device
MOU adds an FDA-approved dry powder platform to Bespak’s intranasal drug delivery offering. Editor’s Take: Nasal drug delivery is gaining attention for its potential to deliver therapies to the central nervous system (CNS) and throughout…
Researchers Map How Nanoparticles And Predictive Models Could Improve Brain Drug Delivery
From tuning nanoparticle size and surface chemistry to modeling their path through the brain, researchers are testing several ways to get therapies past one of medicine’s toughest biological barriers. Rapid advances in NP technology,…
AptarGroup (NYSE:ATR) Now Covered by Deutsche Bank Aktiengesellschaft
Check Out Our Latest Stock Analysis on ATR AptarGroup, Inc NYSE: ATR is a global company that designs and manufactures dispensing, drug-delivery and packaging solutions. Its products are used by pharmaceutical, consumer health, beauty,…
CraniUS Therapeutics Secures Second FDA 510(k) Clearance in Six Weeks and Earns U.S. Patent for NeuroPASS™ 3 Cranial Drug Delivery System
Oct 07, 2026, 07:50 ET Newly cleared CraniUS® Plate configuration, designated NeuroPASS 2, adds an opening designed to accommodate an implantable intracranial pressure sensor; issued patent protects the integrated drug delivery…
Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio
Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio - New Dyno-yp2 capsid achieves both exceptional brain transduction and significant liver detargeting in…
Automated accuracy: Blend reimagines delivery-point dosing
Operational insights for the bulk logistics industry Blend System introduces Blend, the first automated pneumatic dosing system for bulk petroleum tankers, developed in association with AlumiTank to improve additive accuracy, safety, and…
Aptar Pharma Launches Premia™ Precision, a New Quality Standard for Demanding Injectable Therapies
BioSpace Aptar Pharma Launches Premia™ Precision, a New Quality Standard for Demanding Injectable Therapies New quality standard combines impact-based quality limits, advanced contamination and defect control measures, and 100% vision…
Polyrizon Files New U.S. Patent Application for Mucoadhesive Nasal Drug Delivery Platform
Polyrizon files a U.S. divisional patent application for its mucoadhesive technology in nasal drug delivery applications. Polyrizon's new patent application focuses on its proprietary mucoadhesive platform for nasal drug delivery systems.…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
contractpharma.com3
-
aptar.com2
-
aptapassengertransport.com1
-
bastillepost.com1
-
biospace.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.